Back to top

Submissions

MS Australia's advocacy team is regularly looking for opportunities to contribute to policy development and government reviews.

       

MS Australia Submissions:


Note: (1) : joint submission with MS
             
(2) : joint submission with MS Research Australia
                (3) : joint submission with Neurological Alliance Australia (NAA)


2018

Senate Select Committee Inquiry on Charity Fundraising
Implementation of the NDIS in NSW (1)
Vic Government Draft Disability Action Plan 2018-2020 (1)
Regulation of mobility scooters
Implementation of the NDIS in the ACT  (1)

 

2017

 

2016

Continuity of Support program
Pharmacy Remuneration and Regulation
New Disability Employment Services from 2018
ILC Commissioning framework
Election Commitments: Submission to the major parties for the 2016 Federal Election (2)
Vic State Disability Plan 2017-2020 (1)
Submission to the NDIS inquiry into accommodation for people with disabilities and the NDIS
Submission to TGA re Poisons Standard for Medicinal Cannabis (2)
Inquiry into the Public Health (Medicinal Cannabis) Bill - Qld (2)
Services for people with psychosocial disabilities

 

2015

MS Australia Willing to Work Submission
NDIS Quality and Safeguard Framework Submission
Victorian Law Reform Commission's Medicinal Cannabis Issues Paper (2)
NDIS Information, Linkages and Capacity Building (ILC) Policy Framework
Senate Legal and Constitutional Affairs Legislation Committee Inquiry- Medicinal Cannabis Bill (2)
Young people in res care inquiry
Cannabis Use for Medical Purposes ACT bill (2)
TGA Regulations Stem Cells Submission
Disability Advocacy Framework consultation
Increasing choice in home care Stage 1
New aged care short-term restorative care program

 

2014

McClure Welfare Review Submission
Airline two wheelchair policy
Federal Senate Inquiry - Out-of-pocket health costs

 

2013

Legal capacity for people with a disability - National Disability Services review of legislation

 


 

MS Australia Submissions to the Pharmaceutical Benefits Advisory Committee:
 

One area of advocacy we are particularly passionate about is advocating for greater access to affordable treatments for people with MS. MSA and MS Research Australia work together closely on treatment and research advocacy. No two cases of MS are the same and there is no one size fits all treatment for the disease. MS Australia regularly makes submissions supporting the listing of MS treatments on the Pharmaceutical Benefits Scheme (PBS) so that people with MS and their neurologists have greater choice and flexibility to find the treatment method that best suits them. The research and medication information contained in these submissions is provided by MS Research Australia.


2018
MAVENCLAD for RRMS re-submission – July PBAC Review
MAVENCLAD for RRMS re-submission – March PBAC Review
 

2017
Copaxone for Clinically Isolated Syndrome -  PBAC Review
MAVENCLAD for RRMS -  PBAC Review
Ocrevus for RRMS -  PBAC Review
Ocrevus for PPMS -  PBAC Review


2016
Daclizumab - PBAC Review


2015
Copaxone 40 - PBAC Review
 

2014
Expressed Authority -  PBAC Review
Fampyra - PBAC Review
Lemtrada - PBAC Review
Lemtrada (additional) - PBAC Review
Plegridy - PBAC Review


2013
Aubagio - PBAC Review
Tecfidera - PBAC Review